What Is Difference in Conditions Insurance and Does Your Life Sciences Company Need It?

Difference in conditions insurance is a coordinating layer that sits over a life sciences company’s local policies in each country it operates in and fills the gaps between them, so the protection is the same everywhere the company touches. A device manufacturer selling into eight countries, a clinical lab handling specimens from three foreign collection sites, and a digital health platform with users on four continents all face the same structural problem: the local policies in each jurisdiction were written to local standards and do not align. DIC is the instrument that reconciles them.

What DIC Actually Does

A DIC policy is not a primary policy. It sits over a schedule of underlying policies, often local admitted policies in each country, and pays the difference when a local policy provides less coverage than the company’s home-country master program does. The master program defines the standard. The local policies meet local regulatory and admitted-market requirements. The DIC layer makes up the shortfall whenever a local policy responds with a narrower scope, a lower limit, a different deductible, or a different defense structure than the master.

This is structurally different from a worldwide policy. A worldwide policy attempts to cover everywhere from one form, which can run into admitted-market requirements that prohibit non-admitted insurance for certain risks in certain countries. A DIC program respects the requirement to carry local admitted coverage and uses the DIC layer to deliver consistent protection on top. Most life sciences companies operating in more than two or three countries land on the DIC structure for exactly this reason.

When a Life Sciences Company Reaches the DIC Threshold

The conversation tends to start at the same operational triggers. A device manufacturer signing distribution agreements in multiple countries discovers that each agreement specifies local insurance with reciprocal additional insured terms, and the company is suddenly maintaining several local policies whose coverage does not match the US master program. A CRO running studies across borders carries local clinical trial liability in each country with different limit structures and indemnification expectations. A digital health company with European users carrying local cyber that addresses GDPR is finding the local form does not include the breadth of the US cyber. In each case the company is operating with a patchwork rather than a program.

The patchwork is the problem. A claim that breaks across two policies, or a claim in a country where the local policy responds narrowly, exposes the company to the gap. DIC removes the gap by treating the master program as the standard everywhere, the same logic that underlies the question of whether the US program reaches international distribution at all.

Where DIC Most Often Earns Its Keep

Three exposures show DIC’s value most clearly. Products liability for a device sold in countries with varying tort regimes is the most common, because the local Product Liability Directive policy in one country and the local form in another do not respond the same way to the same claim. Clinical trial liability for a multi-country study is the second, since the local CTL policy in each jurisdiction follows that country’s requirements and the sponsor needs consistent protection regardless of which site is involved, an exposure layered on top of the structure in clinical trial insurance for sponsors and CROs. Cyber for a platform with users in several countries is the third, because each jurisdiction’s privacy regime drives a different local cyber form, and the company needs uniform breach-response and regulatory-defense coverage across all of them.

DIC also typically addresses currency. The master program denominates limits and defense in the company’s home currency, and the DIC layer pays in that currency even when the underlying local policy paid in the local one, so foreign-exchange erosion does not silently shrink the cover.

When DIC Is Not the Right Tool

A US-only company does not need DIC. A company operating in one or two foreign countries with stable, well-matched local policies may find a territory extension on the master policy cheaper and simpler than a DIC layer. DIC adds value when the number of jurisdictions, the variation between local policies, and the company’s exposure to consistent claim handling justify the coordinating layer. A broker who recommends DIC without showing the gap analysis between the master and each local form has not done the work that the structure requires.

What to Do Now

If your life sciences company operates in more than two countries, ask your broker to lay the US master program side by side with each local policy and identify where they do not match in limits, scope, defense, or currency. That mapping is the deliverable that tells you whether you need DIC, a territory extension, or a different parallel international placement. The structure is decided by the gap analysis, not by a generic recommendation.

Before your next foreign-market expansion, confirm whether your company is carrying a coordinated international program or a patchwork of local policies that do not align. A specialty review through Tower Street Insurance can map a life sciences company’s local policies against a master standard and show whether a DIC structure or a different international solution fits the footprint.